Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Research To Practice | Oncology Videos · Dr. Neil Love
April 16, 202543m 18s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Raajit K Rampal, including the following topics:
- Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00)
- Novel research strategies involving CDK4/6 inhibitors for MF (8:03)
- Implications of the JUMP study for clinical practice (10:00)
- Therapeutic switching strategies with JAK inhibitors for MF (12:17)
- Clinical rationale for the use of luspatercept and elritercept for MF (15:35)
- Emerging clinical data involving BET inhibitors for MF (16:57)
- Tolerability concerns with selinexor in patients with MF (20:01)
- Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32)
- Additional novel strategies under clinical investigation for MF (25:52)
- Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40)
- Management of polycythemia vera and essential thrombocythemia (34:27)
- General management principles for myeloproliferative neoplasms (37:53)